Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- June 30, 2021 Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
- June 23, 2021 Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
- June 3, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- May 25, 2021 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
- May 14, 2021 Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
- May 12, 2021 Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
- April 28, 2021 Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
- April 21, 2021 Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
- April 16, 2021 Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- April 13, 2021 Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
Displaying 21 - 30 of 40